Drug intelligence / Profile preview

Credelio Plus

Development stage
Unknown
Lead developer
Elanco
Modality
Small Molecules
Administration
Oral
01

Overview

Credelio Plus is an oral **small-molecule combination veterinary antiparasitic** chewable tablet for dogs developed by Elanco. It contains **lotilaner**, an isoxazoline ectoparasiticide that inhibits parasite **gamma-aminobutyric acid gated chloride channels**, and **milbemycin oxime**, a macrocyclic lactone endoparasiticide that acts on invertebrate ligand-gated chloride channels to control susceptible nematodes and support heartworm prevention. The product is used once monthly with food in dogs at least 8 weeks of age and at least 4.4 pounds for the treatment and prevention of **flea infestations**, treatment and control of **tick infestations**, **prevention of heartworm disease** caused by *Dirofilaria immitis*, and treatment of gastrointestinal and certain cardiopulmonary nematode infections including *Toxocara canis*, *Ancylostoma caninum*, *Toxascaris leonina*, *Trichuris vulpis*, and *Angiostrongylus vasorum*.

Brand names
Credelio Plus
Other names
lotilaner + milbemycin oxime
02

Targets

RDL (Insect GABA-gated chloride channel)GluCl (Glutamate-gated chloride channel)

Beyond the preview

Go deeper on Credelio Plus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Credelio Plus.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call